Video
Dr. Garcia-Carbonero on Quality of Life Impact of FOLFIRI Plus Ramucirumab in mCRC
Author(s):
Rocio Garcia-Carbonero, MD, PhD, Universidad de Sevilla, discusses the quality of life results from the RAISE study. The RAISE study was a phase III randomized, double-blind study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal cancer (mCRC) after first-line therapy with bevacizumab, oxaliplatin, or fluoropyrimidine.
Rocio Garcia-Carbonero, MD, PhD, Universidad de Sevilla, discusses the quality of life results from the RAISE study.
The RAISE study was a phase III randomized, double-blind study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal cancer (mCRC) after first-line therapy with bevacizumab, oxaliplatin, or fluoropyrimidine.
Quality of life scores were calculated based on physical functioning, role functioning, emotional functioning, fatigue, appetite loss, and constipation. Results found that there was a transient worsening in quality of life for the FOLFIRI plus ramucirumab arm compared to the placebo plus FOLFIRI arm. However, differences in most quality of life scores were not significantly significant between the two arms.
